Researchers for the LIGHTSITE III trial investigated the efficacy of multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD). PBM-treated eyes showed statistically significant visual improvements and lower rates of new geographic atrophy lesions compared with sham-treated eyes. The study noted limitations and called for future research to explore broader patient populations and potential adjunctive use of PBM therapy.

Source: Retina